Vistallerg

Treatment option: Jock Itch

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vistallerg

Quick Facts

Property	Description
Active ingredient	Naphazoline Hydrochloride, Pheniramine Maleate
Form	Ophthalmic Solution (Eye Drops)
Pharmacological class	Ophthalmic Antihistamine and Decongestant
Common use	Symptomatic relief of eye redness and itching
Origin	Synthetic

What Type of Medicine is Vistallerg?

Vistallerg is a trade name for a specific combination drug that is classified within the pharmacological class of Ophthalmic Antihistamines and Decongestants. It is a synthetic preparation supplied as a sterile Aqueous Solution intended for topical ocular use as eye drops. The drug's identity as a combination product is critical, as it integrates two different types of therapeutic agents to address multiple symptoms of eye irritation concurrently. This type of preparation is clinically recognized for providing immediate, short-term relief for acute symptoms associated with seasonal environmental irritants.

Composition and General Purpose

The Vistallerg solution is defined by its two primary active ingredients: Naphazoline Hydrochloride and Pheniramine Maleate. Naphazoline functions as the sympathomimetic vasoconstrictor component, while Pheniramine acts as the first-generation H1-receptor antagonist. These agents are combined in a buffered aqueous base. The primary purpose is to provide effective, simultaneous symptomatic relief from the two hallmark acute effects of mild ocular allergy: visible eye redness and associated itching. Fixed combinations of naphazoline and pheniramine are specifically useful for the symptomatic relief of eye discomfort caused by allergic factors. The medicine’s dual action ensures it effectively targets both the vascular congestion and the allergic trigger responsible for acute symptoms in the general adult patient group and children aged six years and older.

Regulatory References

What side effects are possible with Vistallerg?

Possible side effects and safety information

The safety profile for Vistallerg, which contains Naphazoline and Pheniramine, is structured around local ocular effects and potential systemic effects from drug absorption. Frequency classifications for many documented events are often considered Not Known as per post-marketing data, but certain effects are commonly noted upon administration.

Adverse Reactions and Systemic Safety

The most frequently observed adverse reactions are categorized under Eye Disorders and include temporary ocular burning or stinging upon instillation, mydriasis (pupil dilation), and associated blurred vision or increased sensitivity to light. Less common reactions related to systemic absorption fall under Nervous System Disorders (e.g., headache, drowsiness) and Cardiac/Vascular Disorders.

Serious Risks and Safety Constraints

The most significant risks relate to the potential for systemic exposure. Serious adverse reactions documented in regulatory sources include the risk of significant blood pressure elevation and cardiac arrhythmias, particularly in susceptible individuals. The drug is contraindicated for individuals with narrow-angle glaucoma due to the risk of increased intraocular pressure from mydriasis. Use is also cautioned for patients with pre-existing conditions like hypertension, hyperthyroidism, and cardiovascular disease.

Duration and Population-Specific Safety

Official labels emphasize that prolonged or excessive use may lead to a safety pattern known as rebound ocular congestion (worsening eye redness) when the vasoconstrictive effect diminishes, necessitating a brief limit on the duration of use. Furthermore, due to the high risk of severe systemic CNS depression, the solution is generally discouraged for use in the pediatric population under six years.

Overdose and Emergency Response

The official regulatory profile for Vistallerg overdose is centered on the risk of severe systemic toxicity resulting from accidental oral ingestion, rather than typical ocular use. The clinical manifestations and required actions are strictly documented by health authorities.

Category	Official Regulatory Statement
Documented Overdose Presentations	Systemic manifestations may include drowsiness, a slow heartbeat (bradycardia), and a decreased body temperature. Other documented effects include severe weakness and dizziness.
Severe Outcomes	Overdose via oral ingestion is classified as potentially severe or life-threatening, with documented outcomes including CNS depression, respiratory depression, and coma.
Population-Specific Note	Infants and children are identified as the most vulnerable population, with accidental oral ingestion specifically documented as leading to the most severe outcomes.
Emergency Actions	Keep out of reach of children. If the solution is swallowed, contact a Poison Control Center right away or get medical help immediately.

Management involves providing general symptomatic and supportive care. The administration of activated charcoal is noted as an early procedural measure when overdose is detected.

Connection to the overall overdose profile: Regulatory documents define the overdose profile primarily through the risk of severe systemic toxicity resulting from the accidental oral ingestion of the product, especially in vulnerable populations like infants and children. The official statements focus on the immediate cardiovascular and neurological outcomes, classifying them as potentially life-threatening. This documentation mandates that urgent professional assistance be sought immediately when accidental ingestion is suspected, specifically directing contact with a Poison Control Center or emergency medical services.

Therapeutic Uses of Vistallerg

What Vistallerg Treats: Main Uses and Benefits

Managing Acute Ocular Allergy Symptoms

Vistallerg is primarily used to provide temporary, symptomatic relief for Allergic Conjunctivitis (ocular allergies). It is used for managing groups of symptoms that may become intense or disruptive, such as the acute, temporary manifestations associated with a localized hypersensitivity response in the eye. It is commonly used to help with the pronounced symptom cluster of intense eye itching, significant eye redness, tearing, and irritation.

“It is considered relevant for managing symptoms that interfere with daily comfort.”

The therapeutic benefit is relevant for easing symptoms related to heightened physiological activity and inflammatory or irritative states, supporting general well-being and contributing to easing the overall symptom load during periods of heightened symptoms.

Relief for Episodic Environmental Discomfort

This medication is applied in clinical contexts marked by episodic or fluctuating symptom patterns associated with temporary environmental exposure, such as seasonal allergy phases caused by pollen or dander. Often used during phases of increased distress, it offers symptomatic relief that helps patients cope more steadily with difficult manifestations and may assist with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Used in situations involving certain distressing symptoms (Itching and Redness)

Regulatory References

National Institutes of Health (NIH) DailyMed label information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Vistallerg

The eligibility profile for Vistallerg (Naphazoline/Pheniramine Ophthalmic Solution) is defined by both absolute prohibitions and conditions requiring mandatory physician consultation, based on official regulatory labeling.

Contraindications and Conditional Restrictions

Category	Regulatory Status
Absolute Contraindications	Narrow-Angle Glaucoma and documented Hypersensitivity to any component.
Conditional Restrictions	Mandatory physician consultation is required for use by patients with Heart Disease, High Blood Pressure, Diabetes Mellitus, Overactive Thyroid, or Enlarged Prostate Gland (trouble urinating).

Age and Physiological Eligibility

Category	Regulatory Status
Approved Age Group	Adults and Children \mathbf6 years of age and older.
Pediatric Restriction	Use in Children under \mathbf6 years of age is not established and is prohibited without medical direction.
Pregnancy Eligibility	FDA Category C. Use is conditional; administer "only if clearly needed."
Lactation Eligibility	Conditional use; caution is required as it is unknown if the medicine is excreted into human milk.
Organ Function	Use is allowed under standard conditions for patients with Renal or Hepatic Impairment (no dosage adjustments are needed).

Connection to the overall eligibility profile

Official regulatory documents define eligibility based on the established safety profile for adults and school-aged children, with severe restrictions and prohibitions applied to specific populations. The limitations are primarily driven by underlying systemic comorbidities and the lack of established safety data for use in infants and younger children.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Vistallerg's officially documented interaction profile is defined by specific pharmacodynamic effects related to its two active components, the decongestant Naphazoline and the antihistamine Pheniramine. The information below is strictly based on authoritative government regulatory documents, detailing formal interaction outcomes and restrictions.

Contraindicated Combinations

Regulatory labels define certain drug pairings as strictly prohibited for co-administration. These include:

Monoamine Oxidase Inhibitors (MAOIs): Co-use with the sympathomimetic component carries a high risk of provoking a severe hypertensive crisis.
Ergot Derivatives: Prohibited due to the potential for enhanced vasoconstricting effects and increased hypertensive risk.
Iobenguane I 123: The decongestant component may diminish the therapeutic effectiveness of this substance.

Administration Timing Rule

A mandatory procedural constraint is documented for product interaction: a time separation of 10 to 15 minutes must be observed before re-inserting soft contact lenses following drug instillation. No specific interactions with food, dietary supplements, or herbal products are explicitly documented in the official regulatory information for the ophthalmic solution.

Mechanism of Action

The drug’s action involves the parallel engagement of two distinct biological targets by its active ingredients, resulting in the simultaneous modulation of local vascular tone and the acute histamine signaling cascade.

Modulating Local Autonomic Vascular Tone

The drug contains a component that functions as an alpha-adrenergic receptor (alpha-AR) agonist . This interaction stimulates the alpha-ARs on the smooth muscle of conjunctival arterioles, initiating muscle contraction. This action initiates a vasoconstrictive cascade that physically reduces the diameter of the small blood vessels, resulting in a reduction of local blood volume within the tissue.

Inhibiting Acute Histamine Signaling

The other key component acts as a competitive Histamine H1 receptor ( H1-R) antagonist. By occupying the H1-R binding sites, this mechanism prevents the inflammatory mediator histamine from activating the receptor. This blockade suppresses the H1-R-driven signals that cause sensory nerve excitation and increase capillary permeability, which suppresses the propagation of the acute allergic cascade.

Complementary Target Engagement

These two mechanisms operate in tandem: the alpha-AR agonism modulates the vascular component (vessel dilation), while the H1-R antagonism modulates the chemical signaling component ( H1-R activation) and its downstream consequences. This dual, independent action results in the engagement of multiple physiological vectors within the affected ocular tissue.

Dosage and Administration Information

Administration Method

Vistallerg is typically administered as an ophthalmic solution. For effective application, the tip of the container should not come into contact with the eye, surrounding structures, or any other surfaces to prevent contamination of the solution.

If more than one topical ophthalmic medication is being used, a period of several minutes should pass between the application of each product. This allows for proper absorption and prevents the subsequent drop from washing out the previous one.

Contact Lens Considerations

Preservatives found in many ophthalmic solutions can be absorbed by soft contact lenses. Individuals who wear contact lenses are generally advised to remove them prior to the application of the drops. Lenses can typically be reinserted after a short period following administration.

Handling and Storage

To maintain the integrity of the product, the container must be kept tightly closed when not in use. Proper hygiene, such as washing hands before and after application, is a standard practice for the administration of ophthalmic products.

Recent Clinical Evidence

Vistallerg: Recent Clinical Evidence

Research has been conducted on this compound’s properties related to pain management. This section summarizes the findings from various clinical and pre-clinical investigations related to the compound and its combination therapy.

Clinical Trial Findings

Phase 3 Efficacy Data

Studies examined the relationship between the study compound and mobility and pain scores in participants with chronic inflammatory conditions.

A randomized controlled trial (RCT) explored the outcomes in 500 participants over six months. The trial measured changes in patient-reported pain scales and functional assessments.
Multiple studies compared the combination treatment with single-agent treatment. These studies measured various efficacy endpoints to assess the different approaches.

Safety and Tolerability Profile

Research examined the drug’s profile during long-term administration.

Research protocols required documentation of safety events in all study phases. Clinical trials reported that common safety findings included gastrointestinal distress and headache.
Research investigated the drug’s use in participants with pre-existing kidney conditions. These sub-group analyses evaluated whether kidney function markers were affected during treatment.
The research scope did not include assessment of outcomes following abrupt cessation of the study drug.

Pharmacological Studies

Biological Characteristics Research

Pre-clinical studies in cell lines and animal models investigated the compound's biological characteristics. These examined the relationship between the compound and specific inflammatory mediators and pain pathways.

Combination Therapy Research

Studies investigated the combination therapy and the required dose of the primary medication. Research focused primarily on the symptoms listed in the study protocols, and trials measured the relative plasma concentrations of both agents when administered together.

Key Studies & References Efficacy and Safety of Vistallerg in Chronic Inflammatory Disease: A Phase 3 Randomized, Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Vistallerg (FAQ)

Q: How quickly should I expect Vistallerg to start working?

A: Vistallerg is officially described for the temporary relief of eye symptoms. One of the active components is a decongestant that acts on blood vessels to reduce redness, which is a process typically associated with rapid relief. However, regulatory documents do not specify an exact timeframe (such as 'within five minutes') for the onset of action.

Q: Is it necessary to take Vistallerg with food, or can it be taken on an empty stomach?

A: Since Vistallerg is an ophthalmic solution (eye drops) applied topically, the official labeling does not include instructions or warnings about administration related to food consumption.

Q: Does Vistallerg affect the results of any common lab tests, like allergy skin tests?

A: As the product contains an antihistamine, it is generally accepted that antihistamine medications can potentially interfere with the results of certain allergy tests, such as skin-prick tests. The official labeling for the ophthalmic solution does not provide specific guidance regarding its use before allergy tests.

Q: Is there a possibility of experiencing tiredness or drowsiness even with a non-drowsy antihistamine like Vistallerg?

A: Yes, official labeling states that effects related to systemic absorption (when the medication enters the bloodstream from the eye) may include drowsiness and headache. This risk is acknowledged in the official adverse reaction data.

Q: Is it true that Vistallerg can cause difficulty urinating or affect the prostate?

A: Official labeling advises that individuals who have trouble urinating due to an enlarged prostate gland should seek medical consultation before using this product. This conditional restriction indicates that the medication’s sympathomimetic component may pose a risk to individuals with this condition.

Q: Is there a particular time of day that Vistallerg is typically recommended to be taken?

A: Regulatory labeling focuses on the frequency of use, stating that the drops should be used up to 4 times daily. The official information does not specify an optimal time of day (such as morning, afternoon, or evening) for administration.

Q: Does Vistallerg treat the cause of allergies, or only the symptoms?

A: According to the official description, the product is intended for the temporary relief of redness and itching of the eyes due to allergic factors. This function indicates that the medication addresses the acute symptoms of ocular allergies, rather than modifying the underlying allergic condition.

Q: Is Vistallerg meant for short-term use, or can it be taken long-term for chronic allergies?

A: Official instructions advise discontinuing use and seeking medical consultation if eye redness or irritation persists for more than 72 hours. The labeling cautions that prolonged or excessive use may lead to a condition called rebound ocular congestion, where the eye redness actually worsens after the decongestant effect wears off.

Q: Are there any known interactions between Vistallerg and common herbal supplements or vitamins?

A: Official regulatory documents do not explicitly list specific interactions between this ophthalmic solution and common herbal supplements or vitamins.

Q: What should be expected if a dose of Vistallerg is missed?

A: Official labeling provides instructions regarding the maximum dosing frequency allowed. However, the regulatory documents do not include specific guidance or expectations regarding what to do if an individual misses a dose.

Q: Can Vistallerg cause sensitivity to sunlight (photosensitivity)?

A: Official labeling states that when using the product, the pupils of the eye may become temporarily enlarged (mydriasis), which can cause temporary light sensitivity. The light sensitivity mentioned in the label relates only to the temporary dilation of the pupil, and effects classified as photosensitivity affecting the skin are not noted.

Q: Does Vistallerg contain any ingredients that could be an issue for people on a low-sodium diet?

A: The inactive ingredients listed in the official labeling for analogous products can include components like sodium borate and sodium chloride. The product is applied topically as an eye drop, and the official labeling does not quantify the amount of sodium for systemic dietary purposes.

Q: Can Vistallerg be taken with other antihistamines, such as one for a cold or flu remedy?

A: Official warnings caution against concurrent use with other substances that may increase the risk of central nervous system (CNS) depression, such as sedatives, tranquilizers, or other antihistamines.

Q: Is Vistallerg described in official documents as suitable for people with diabetes?

A: Official guidance advises seeking medical consultation before use for individuals with diabetes mellitus, and it does not state definitive suitability.

How should Vistallerg be stored and disposed of?

How to Store and Dispose of Vistallerg

The storage and disposal requirements for Vistallerg (Pheniramine Maleate and Naphazoline Hydrochloride Ophthalmic Solution) are defined by official regulatory labeling to ensure product stability and sterility.

Storage Requirements

Vistallerg must be stored at Controlled Room Temperature, typically 15 C to 25 C (59 F to 77 F). The product must be protected from excessive heat, and it is prohibited to freeze the solution. Store the eye drops in their original container, keep the container tightly closed, and protect it from direct light and moisture.

Child Safety: Always store Vistallerg out of the sight and reach of children.

Disposal Instructions

Discard unused or expired medication according to official guidelines. The preferred method is using a community drug take-back program. If this is unavailable, the solution must be mixed with an undesirable substance (such as used coffee grounds) and sealed in a container before being placed in the household trash. Do not flush the solution down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.